PDF(Pubmed)
Abstract：
Parkinson\'s disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the gut-brain axis. Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles and clinical trials regarding GLP-1R agonists and PD published in the English language with no time restrictions. We also screened the references of the selected articles for possible additional articles in order to include most of the key recent evidence. Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD. Evidence from clinical studies is also very promising, enhancing the possibility of adding GLP1-R agonists to the current armamentarium of drugs available for PD treatment.
摘要：
帕金森病(PD)是最常见的神经退行性疾病之一。最近的数据强调了神经退行性疾病之间的相似性，包括PD和2型糖尿病（T2DM），表明肠脑轴之间的关键相互作用。胰高血糖素样肽-1受体(GLP-1R)激动剂,以其在T2DM治疗中的应用而闻名，目前作为新型PD改性剂被广泛研究。对于这篇叙述性评论文章，我们在PubMed和Scopus数据库中搜索了同行评审的研究，回顾以英语发表的有关GLP-1R激动剂和PD的文章和临床试验,没有时间限制.我们还筛选了选定文章的参考文献中可能的其他文章，以包括大多数关键的最新证据。许多关于动物模型和临床前研究的数据表明，GLP1-R激动剂可以恢复多巴胺水平，抑制多巴胺能的损失，减轻神经元变性并减轻PD的运动和非运动特征。来自临床研究的证据也非常有希望，增加在目前可用于PD治疗的药物中添加GLP1-R激动剂的可能性。
